Skip to main content

Topic

ANDA Litigation

15 published works

  1. Delaware Intellectual Property Litigation

    Judge Sleet Concludes that Defendants Did Not Prove Invalidity of Asserted Claim in ANDA Action

    By Fox Rothschild LLP

    Following a four day bench trial in a consolidated ANDA action before The Honorable Gregory M. Sleet in Genzyme Corp., et al. v. Dr. Reddy’s Laboratories, Ltd., et al., Civil…

  2. Delaware Intellectual Property Litigation

    Judge Andrews Issues Markman Opinion Construing Three Terms in Dispute in ANDA Action filed by The Medicines Company

    By Fox Rothschild LLP

    By Claim Construction Opinion entered in The Medicines Company v.Teva Parenteral Medicines, Inc. et al., C.A. No. 09-750-RGA (D.Del., July 11, 2013), The Honorable Richard G. Andrews construed three disputed…

  3. Antitrust Law Blog

    FTC v. Actavis: What Does It Mean for Reverse-Payment Settlements?

    By Sheppard Mullin

    By Bradley Graveline and Jennifer Driscoll-Chippendale  On June 17, 2013, the United States Supreme Court announced a rule that blurs the lines between antitrust and patent law in the context of Hatch-Waxman litigation.…

  4. Delaware Intellectual Property Litigation

    Following Seven Day Bench Trial, Judge Robinson Finds Plaintiff Pronova Did Prove Infringement of Its ‘667 and ‘077 Patents by Defendants in ANDA Action

    By Fox Rothschild LLP

    By Opinion issued by The Honorable Sue L. Robinson in Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc., et al., Civil Action No. 09-286-SLR (D.Del., May 29, 2012), the…

  5. Delaware Intellectual Property Litigation

    Chief Judge Sleet Concludes that Mylan’s Proposed ANDA Product Does Not Infringe the Patent-In-Suit Asserted by AstraZeneca and Others

    By Fox Rothschild LLP

    By Memorandum Opinion entered by the Honorable Gregory M. Sleet in AstraZeneca LP, et al. v. Mylan Pharmaceuticals Inc., Civil Action No. 08-53-GMS (D.Del., June 23, 2011) after a three day…